Résultats de la recherche - Prabir Chakraborti

  • Résultat(s) 1 - 7 résultats de 7
Affiner les résultats
  1. 1
    Osteonecrosis of the Jaw and Oral Health–Related Quality of Life After Adjuvant Zoledronic Acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial Subprotocol (BIG01/04)

    Osteonecrosis of the Jaw and Oral Health–Related Quality of Life After Adjuvant Zoledronic Acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial Subprotocol (BIG01/04) par Emma Rathbone, Janet E. Brown, Helen Marshall, Michelle Collinson, Victoria Liversedge, Geraldine Murden, David Cameron, Richard H. Bell, S. Spensley, Rajiv K. Agrawal, R. Jyothirmayi, Prabir Chakraborti, Frances Yuille, Robert E. Coleman

    Publié 2013
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  2. 2
    TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer

    TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic... par Nicholas D. James, Sarah Pirrie, Ann Pope, Darren Barton, Lazaros Andronis, Ilias Goranitis, Stuart I. Collins, Duncan B. McLaren, Joe M. O’Sullivan, Chris Parker, Emilio Porfiri, John Staffurth, Andrew Stanley, James Wylie, S. Beesley, Alison Birtle, J. Martin Brown, Prabir Chakraborti, Martin Russell, Lucinda Billingham

    Publié 2016
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  3. 3
    Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both

    Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both par Nicholas D. James, Sarah Pirrie, Ann Pope, Darren Barton, Lazaros Andronis, Ilias Goranitis, Stuart I. Collins, Adam Daunton, Duncan B. McLaren, Joe M. O’Sullivan, Christopher Parker, Emilio Porfiri, John Staffurth, Andrew Stanley, James Wylie, S. Beesley, Alison Birtle, Janet E. Brown, Prabir Chakraborti, Syed A. Hussain, Martin Russell, Lucinda Billingham

    Publié 2016
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  4. 4
    Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial

    Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial par Alison Birtle, Mark Johnson, John Chester, Robert J. Jones, David Dolling, Richard T. Bryan, Christopher Harris, Andrew Winterbottom, Anthony Blacker, James W.F. Catto, Prabir Chakraborti, Jenny Donovan, Tony Elliott, Ann French, Satinder Jagdev, Benjamin Jenkins, Francis X. Keeley, Roger Kockelbergh, Thomas Powles, John Wagstaff, Caroline Wilson, Rachel Todd, Rebecca Lewis, Emma Hall

    Publié 2020
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  5. 5
    Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, plat... par Nicholas D. James, Matthew R. Sydes, Noel W. Clarke, Malcolm D. Mason, David P. Dearnaley, Melissa Spears, A.W.S. Ritchie, Christopher Parker, John M. Russell, Gerhardt Attard, Johann S. de Bono, William Cross, Robert J. Jones, George N. Thalmann, Claire Amos, David Matheson, Robin Millman, Mymoona Alzouebi, S. Beesley, Alison Birtle, Susannah Brock, Richard Cathomas, Prabir Chakraborti, Simon Chowdhury, Audrey Cook, Tony Elliott, Joanna Gale, Stephanie Gibbs, John D. Graham, John Hetherington, Robert Hughes, Robert Laing, Fiona McKinna, Duncan B. McLaren, Joe M. O’Sullivan, Omi Parikh, C. Peedell, Andrew Protheroe, Angus Robinson, Narayanan Srihari, Rajaguru Srinivasan, John Staffurth, Santhanam Sundar, Shaun Tolan, David Tsang, John Wagstaff, Mahesh Parmar

    Publié 2015
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  6. 6
    Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy par Nicholas D. James, Johann S. de Bono, Melissa Spears, Noel W. Clarke, Malcolm D. Mason, David P. Dearnaley, A.W.S. Ritchie, Claire Amos, Clare Gilson, Robert J. Jones, David Matheson, Robin Millman, Gerhardt Attard, Simon Chowdhury, William Cross, Silke Gillessen, Christopher Parker, John M. Russell, Dominik Berthold, Christopher D. Brawley, F. Adab, San Aung, Alison Birtle, Jo Bowen, Susannah Brock, Prabir Chakraborti, Catherine Ferguson, Joanna Gale, Emma Gray, Mohan Hingorani, Peter Hoskin, J.F. Lester, Zafar Malik, Fiona McKinna, Neil McPhail, Julian Money‐Kyrle, Joe M. O’Sullivan, Omi Parikh, Andrew Protheroe, Angus Robinson, Narayanan Srihari, Carys Thomas, John Wagstaff, James Wylie, Anjali Zarkar, Mahesh Parmar, Matthew R. Sydes

    Publié 2017
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  7. 7
    Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

    Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-infer... par Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory, Christy Ralph, Anthony Maraveyas, Omar Din, Timothy Eisen, Paul Nathan, Tom Powles, Richard Griffiths, Robert J. Jones, Naveen Vasudev, Matthew Wheater, Abdel Hamid, Tom Waddell, R. McMenemin, Poulam M. Patel, James Larkin, Guy Faust, Adam Martin, Jayne Swain, Janine Bestall, Christopher McCabe, David Meads, Vicky Goh, Tze Min Wah, Julia Brown, Jenny Hewison, Peter J. Selby, Fiona Collinson, Judith Carser, Gopalakrishnan Srinivasan, Fiona Thistlewaite, Ashraf Azzabi, Mark Beresford, David Farrugia, M. Decatris, Carys Thomas, Joanna Gale, James J McAleer, Alison Clayton, Ekaterini Boleti, T. Geldart, Santhanam Sundar, J.F. Lester, Nachi Palaniappan, Mohan Hingorani, Khaliq Rehman, Mohammad Adil Khan, Naveed Sarwar, Janine Graham, Alastair Thomson, Narayanan Srihari, Denise Sheehan, R. Srinivasan, Omar Khan, Andrew Stockdale Jane Worlding, Stergios Boussios, N Stuart, Carey MacDonald-Smith, Falalu Danwata, Duncan McLaren, Aravindhan Sundaramurthy, Anna Lydon, S. Beesley, Kathryn Lees, Mohini Varughese, Emma Gray, Angela C Scott, Mark Baxter, Anna Mullard, Pasquale F. Innominato, Gaurav Kapur, Anil Kumar, Natalie Charnley, Caroline Manetta, Prabir Chakraborti, Prantik Das, Sarah Rudman, Henry F. Taylor, Christos Mikropoulos, Martin Highley, D. Muthukumar, Anjali Zarkar, Roy Vergis, Seshadri Sriprasad, Patryk Brulinski, Amanda Clarke, Richard Osbourne, Melanie Harvey, Renata Dega, Geoffrey Sparrow, U. Barthakur, Erica Beaumont, Caroline Manetta, Agnieszka Michael, Emilio Porfiri, Faisal Azam, Ravi Kodavtiganti

    Publié 2023
    Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:

Outils de recherche: